Professor John Petrie

Director of the Robertson Centre for Biostatistics and Clinical Trials Unit and Professor of Diabetes (Robertson Centre for Biostatistics)

telephone: 0141 330 4744 (RCB reception)
email: John.Petrie@glasgow.ac.uk

Room 334, CAMS Research Institute, Bhf Gcrc, Glasgow G12 8TA

Biography

Professor Petrie graduated from Edinburgh University medical school in 1989. His early clinical training was in Glasgow followed by a PhD on insulin sensitivity and endothelial function (1997) and further clinical and postdoctoral training at the University of Glasgow. He was Reader in Diabetic Medicine at the University of Dundee from 2003 where he led the initiation and successful establishment of the Scottish Diabetes Research Network (SDRN). He returned to Glasgow in 2010 to a chair in Diabetic Medicine.

Throughout his career he has been a driving force in a number of productive national and international research networks, notably the European Group for the Study of Insulin Resistance, of which he was President from 2010 to 2015.

He has made significant contributions to national and international guidelines for health professionals. For example, as member of the joint American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Technology Committee, he was lead author in 2015 of a statement on the risks and benefits of Insulin Pumps. In 2010, he developed the algorithm on glucose-lowering therapies since used nationally in the Scottish Intercollegiate Guidelines Network (SIGN116) guideline on type 2 diabetes.

Professor Petrie was Associate Editor of the journal of the European Association for the Study of Diabetes (EASD) Diabetologia until joining its Advisory Board in 2014. He is currently a Senior Associate Editor of the journal Cardiovascular Endocrinology.

He is a Trustee of the NovoNordisk UK Research Foundation and has served on grant-awarding panels including the US National Institutes of Health (NIH), the US Juvenile Diabetes Research Foundation (JDRF), the National Health and Medical Research Council of Australia (NHMRC), the European Foundation for the Study of Diabetes (EFSD), the UK National Institute for Healthcare Research (NIHR), the Academy of Finland, Diabetes UK, and the Health Research Boards of Ireland.

Research interests

Leader:

Current position

John Petrie is Professor of Diabetic Medicine at the University of Glasgow. He is Honorary Consultant Physician and Diabetologist at Glasgow Royal Infirmary and New Stobhill Ambulatory Care Hospital, Glasgow.

Research interests

Professor Petrie’s research aims to understand and prevent the cardiovascular complications of diabetes with a particular focus on adjunct therapies for type 1 diabetes.

From a background in clinical physiology and biochemistry (insulin assays, euglycaemic clamps, forearm plethysmography), his work has developed into leading academic and pharma-sponsored clinical trials and exploiting well-phenotyped cohorts for biomarker discovery and validation.

Since December 2010 he has been Chief Investigator of REMOVAL, an international double-blind randomized placebo-controlled trial testing the cardiovascular effects of metformin on the complications of type 1 diabetes. REMOVAL (NCT 01483560) is funded by a $4.5M Strategic Research Award from the US Juvenile Diabetes Research Foundation. The trial involves participants in the UK, Denmark, Holland, Canada, and Australia. There are key collaborations with University College London (UK), the University of Wisconsin (USA), the Steno Diabetes Center (Denmark), the NHMRC Clinical Trials Centre (Australia) and the Robarts Research Institute (Canada) - as well as with commercial partner organizations including Merck KGaA (Germany) and Itamar Medical (Israel). Trial Coordination is via the Robertson Centre for Biostatistics (University of Glasgow) and Glasgow Clinical Trials Unit. REMOVAL is on target for completion in 2017.

Professor Petrie is an active member of the SDRN Type 1 Bioresource Steering Committee and serves on clinical trial committees for a number of pharmaceutical companies and contract research organisations including Boehringer-Ingelheim, Novo Nordisk, Quintiles, Roche and Sanofi.

Professor Petrie’s research has been supported financially by the Juvenile Diabetes Research Foundation, the Chief Scientist Office in Scotland, the British Heart Foundation, Diabetes UK, the European Union and industry partners.

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001

Number of items: 145.

2024

Sabatini, S., Nolan, J. J., O'Donoghue, G., Kennedy, A., Petrie, J. , Walker, M., O'Gorman, D. J. and Gastaldelli, A. (2024) Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies. Metabolism, 155, 155910. (doi: 10.1016/j.metabol.2024.155910) (PMID:38599278)

Mesquita, L. A. et al. (2024) Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, (doi: 10.1111/dom.15509) (PMID:38389430) (Early Online Publication)

2023

Zanetti, D. et al. (2023) Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts. Diabetologia, 66(9), pp. 1643-1654. (doi: 10.1007/s00125-023-05946-z) (PMID:37329449)

Chen, D., Jenkins, A. J., Greenlaw, N. , Dudman, K. , Fernandes, T., Carty, D. M., Hughes, A. D., Januszewski, A. S., Stehouwer, C. D. A. and Petrie, J. R. (2023) Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial. Diabetes and Vascular Disease Research, 20(3), p. 14791641231183634. (doi: 10.1177/14791641231183634) (PMID:37387358) (PMCID:PMC10328035)

Wang, H. et al. (2023) Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nation-wide population-based comparative safety study. Diabetes Care, 46(5), pp. 967-977. (doi: 10.2337/dc22-1238) (PMID:36944118) (PMCID:PMC10154665)

Rotbain Curovic, V. et al. (2023) Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – a post-hoc analysis of the PRIORITY randomized clinical trial. Journal of Diabetes and its Complications, 37(4), 108433. (doi: 10.1016/j.jdiacomp.2023.108433) (PMID:36841085)

Broadway, K. A. et al. (2023) Loci for insulin processing and secretion provide insight into type 2 diabetes risk. American Journal of Human Genetics, 110(2), pp. 284-299. (doi: 10.1016/j.ajhg.2023.01.002) (PMID:36693378) (PMCID:PMC9943750)

2022

Timmons, J. G. , Littlejohn, L., Boyle, J. G. and Petrie, J. R. (2022) Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs, 31(12), pp. 1311-1320. (doi: 10.1080/13543784.2022.2159806) (PMID:36655950)

Butterly, E. et al. (2022) Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open, 12(10), e066491. (doi: 10.1136/bmjopen-2022-066491) (PMID:36302574) (PMCID:PMC9621152)

McGurnaghan, S. J. et al. (2022) Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland. BMJ Open, 12(10), e063046. (doi: 10.1136/bmjopen-2022-063046) (PMID:36223968) (PMCID:PMC9562713)

Livingstone, R. , Bryant, N. J., Boyle, J. G., Petrie, J. R. and Gould, G. W. (2022) Diabetes is accompanied by changes in the levels of proteins involved in endosomal GLUT4 trafficking in obese human skeletal muscle. Endocrinology, Diabetes and Metabolism, 5(5), e361. (doi: 10.1002/edm2.361) (PMID:35964329) (PMCID:PMC9471587)

Höhn, A. et al. (2022) Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013–2018. PLoS ONE, 17(8), e0271110. (doi: 10.1371/journal.pone.0271110) (PMID:35951518) (PMCID:PMC9371295)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Yang, Z. et al. (2022) Genetic landscape of the ACE2 coronavirus receptor. Circulation, 145(18), pp. 1398-1411. (doi: 10.1161/CIRCULATIONAHA.121.057888) (PMID:35387486) (PMCID:PMC9047645)

Patarrão, R. S. et al. (2022) Prediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion. Diabetologia, 65(5), pp. 861-871. (doi: 10.1007/s00125-021-05638-6) (PMID:35190847)

Black, H. L. et al. (2022) Knockout of Syntaxin-4 in 3T3-L1 adipocytes reveals new insight into GLUT4 trafficking and adiponectin secretion. Journal of Cell Science, 135(1), jcs258375. (doi: 10.1242/jcs.258375) (PMID:34859814) (PMCID:PMC8767277)

Chamberlain, R. C. et al. (2022) Foot ulcer and risk of lower limb amputation or death in people with diabetes: a national population-based retrospective cohort study. Diabetes Care, 45(1), pp. 83-91. (doi: 10.2337/dc21-1596) (PMID:34782354)

2021

Kulkarni, S., Welsh, P. , Ali, M. and Petrie, J. R. (2021) Quality of life in people with type 2 diabetes; a study in a multi-ethnic clinical trial population. British Journal of Diabetes, 21(2), pp. 210-215. (doi: 10.15277/bjd.2021.315)

Touyz, R. M. et al. (2021) Cardiovascular and renal risk factors and complications associated with COVID-19. CJC Open, 3(10), pp. 1257-1272. (doi: 10.1016/j.cjco.2021.05.020) (PMID:34151246) (PMCID:PMC8205551)

O’Reilly, J. E. et al. (2021) Rising rates and widening socioeconomic disparities in diabetic ketoacidosis in type 1 diabetes in Scotland: A nationwide retrospective cohort observational study. Diabetes Care, 44(9), pp. 2010-2017. (doi: 10.2337/dc21-0689) (PMID:34244330)

Timmons, J. G. et al. (2021) Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: the REMOVAL trial. Diabetes, Obesity and Metabolism, 23(6), pp. 1371-1378. (doi: 10.1111/dom.14350) (PMID:33591613)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

McGurnaghan, S. J. et al. (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, 9(2), pp. 82-93. (doi: 10.1016/S2213-8587(20)30405-8) (PMID:33357491) (PMCID:PMC7832778)

Marx, N., Davies, M. J., Grant, P. J., Mathieu, C., Petrie, J. R. , Cosentino, F. and Buse, J. B. (2021) Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology, 9(1), pp. 46-52. (doi: 10.1016/S2213-8587(20)30343-0) (PMID:33159841)

Jeyam, A. et al. (2021) Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 64, pp. 1320-1331. (doi: 10.1007/s00125-021-05413-7) (PMID:33686483) (PMCID:PMC8099793)

2020

Petrie, J. R. , Boyle, J. G., Ali, K., Smith, C., Morrison, D. and Kar, P. (2020) A post COVID‐19 ‘Marshall Plan’ for type 2 diabetes. Diabetic Medicine, (doi: 10.1111/dme.14439)

Petrie, J. R. (2020) SGLT2 inhibitors and renal complications in type 1 diabetes. Lancet Diabetes and Endocrinology, 8(10), pp. 803-805. (doi: 10.1016/S2213-8587(20)30311-9) (PMID:32946814) (PMCID:PMC7492012)

Caparrotta, T. M. et al. (2020) Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. Diabetes Care, 43(9), pp. 2034-2041. (doi: 10.2337/dc20-0120) (PMID:32581068)

O’Reilly, J. E. et al. (2020) Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia, 63(8), pp. 1626-1636. (doi: 10.1007/s00125-020-05173-w) (PMID:32451572) (PMCID:PMC7351819)

Petrie, J. R. , Rossing, P. R. and Campbell, I. W. (2020) Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes, Obesity and Metabolism, 22(6), pp. 904-915. (doi: 10.1111/dom.13984) (PMID:32009286) (PMCID:PMC7317924)

Colombo, M. et al. (2020) Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 63, pp. 788-798. (doi: 10.1007/s00125-019-05081-8) (PMID:31915892)

Livingstone, R. , Boyle, J.G. and Petrie, J.R. (2020) How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes? Diabetic Medicine, 37(4), pp. 513-521. (doi: 10.1111/dme.13911) (PMID:30697804)

Mengozzi, A., Tricò, D., Nesti, L., Petrie, J. , Højlund, K., Mitrakou, A., Krebs, M., Mari, A. and Natali, A. (2020) Disruption of fasting and post-load glucose homeostasis are largely independent and sustained by distinct and early major beta-cell function defects: a cross-sectional and longitudinal analysis of the relationship between insulin sensitivity and cardiovascular risk (RISC) study cohort. Metabolism, 105, 154185. (doi: 10.1016/j.metabol.2020.154185) (PMID:32061908)

Tofte, N. et al. (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology, 8(4), pp. 301-312. (doi: 10.1016/S2213-8587(20)30026-7) (PMID:32135136)

2019

Fleming, G. A., Petrie, J. R. , Bergenstal, R. M., Holl, R. W., Peters, A. L. and Heinemann, L. (2019) Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care, 43(1), pp. 250-260. (doi: 10.2337/dci19-0062) (PMID:31806649)

Tack, C. J. et al. (2019) Long-term efficacy and safety of combined insulin and GLP-1 therapy: evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 21(11), pp. 2450-2458. (doi: 10.1111/dom.13826) (PMID:31282028) (PMCID:PMC6852575)

McKeigue, P. M. et al. (2019) Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 17(1), 165. (doi: 10.1186/s12916-019-1392-8) (PMID:31438962) (PMCID:PMC6706940)

Mair, C. et al. (2019) Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. Diabetologia, 62(8), pp. 1375-1384. (doi: 10.1007/s00125-019-4900-7) (PMID:31104095) (PMCID:PMC6647722)

McGurnaghan, S. J. et al. (2019) The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 62(4), pp. 621-632. (doi: 10.1007/s00125-018-4806-9) (PMID:30631892)

Manco, M., Mari, A., Petrie, J. , Mingrone, G. and Balkau, B. (2019) One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort. Diabetologia, 62(3), pp. 544-548. (doi: 10.1007/s00125-018-4798-5) (PMID:30594956) (PMCID:PMC6428784)

Petrie, J. R. and Sattar, N. (2019) Excess cardiovascular risk in type 1 diabetes mellitus. Circulation, 139(6), pp. 744-747. (doi: 10.1161/circulationaha.118.038137) (PMID:30715940)

Vella, S. and Petrie, J. R. (2019) Macrovascular disease: pathogenesis and risk assessment. Medicine, 47(2), pp. 65-71. (doi: 10.1016/j.mpmed.2018.11.011)

Petrie, J. R. and Salt, I. P. (2019) Diabetes and vascular disease. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 429-437. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_40)

2018

Read, S. H. et al. (2018) Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: external validation using data from the national Scottish diabetes register. Diabetes Care, 41(9), pp. 2010-2018. (doi: 10.2337/dc18-0578) (PMID:30002197)

Boyle, J. G., Livingstone, R. and Petrie, J. R. (2018) Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clinical Science, 132(15), pp. 1699-1709. (doi: 10.1042/CS20171299) (PMID:30115742)

Jenkins, A. J., Welsh, P. and Petrie, J. R. (2018) Metformin, lipids and atherosclerosis prevention. Current Opinion in Lipidology, 29(4), pp. 346-353. (doi: 10.1097/MOL.0000000000000532) (PMID:29878903)

Siméon, S., Massy, Z., Højlund, K., Lalic, K., Porcellati, F., Dekker, J., Petrie, J. , Currie, G. and Balkau, B. (2018) Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study. BMC Nephrology, 19, 124. (doi: 10.1186/s12882-018-0918-1) (PMID:29855339) (PMCID:PMC5984396)

Petrie, J. R. , Guzik, T. J. and Touyz, R. M. (2018) Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology, 34(5), pp. 575-584. (doi: 10.1016/j.cjca.2017.12.005) (PMID:29459239) (PMCID:PMC5953551)

Griffin, S. J. et al. (2018) Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 22(18), (doi: 10.3310/hta22180) (PMID:29652246)

Bermingham, M. L. et al. (2018) N-glycan profile and kidney disease in type 1 diabetes. Diabetes Care, 41(1), pp. 79-87. (doi: 10.2337/dc17-1042) (PMID:29146600)

Walker, J., Colhoun, H., Livingstone, S., McCrimmon, R., Petrie, J. , Sattar, N. and Wild, S. (2018) Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012-2014): a population-based observational study. Diabetologia, 61(1), pp. 108-116. (doi: 10.1007/s00125-017-4478-x) (PMID:29075822) (PMCID:PMC6448945)

McAllister, D. A. et al. (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation, 138(24), pp. 2774-2785. (doi: 10.1161/CIRCULATIONAHA.118.034986) (PMID:29950404) (PMCID:PMC6287897)

2017

Petrie, J. R. , Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A. and Heinemann, L. (2017) Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care, 40(12), pp. 1614-1621. (doi: 10.2337/dci17-0043) (PMID:29070577)

Petrie, J. R. , Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A. and Heinemann, L. (2017) Improving the clinical value and utility of CGM systems: issues and recommendations : a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia, 60(12), pp. 2319-2328. (doi: 10.1007/s00125-017-4463-4) (PMID:29067486)

Holman, R. R. et al. (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(11), pp. 877-886. (doi: 10.1016/S2213-8587(17)30309-1) (PMID:28917545)

Petrie, J. R. (2017) SGLT2 inhibitors in type 1 diabetes: knocked down, but up again? Lancet Diabetes and Endocrinology, 5(11), pp. 841-843. (doi: 10.1016/S2213-8587(17)30315-7) (PMID:28919060)

Krentz, A. J. and Petrie, J. (2017) Report of the European Group for the Study of Insulin Resistance annual meeting, Dublin, 4–6th May 2017. Cardiovascular Endocrinology, 56(3), pp. 113-116. (doi: 10.1097/XCE.0000000000000131)

Livingstone, R. , Boyle, J. G. and Petrie, J. R. (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 60(9), pp. 1594-1600. (doi: 10.1007/s00125-017-4364-6) (PMID:28770327)

Belongie, K. J., Ferrannini, E., Johnson, K., Andrade-Gordon, P., Hansen, M. K. and Petrie, J. R. (2017) Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk. PLoS ONE, 12(8), e0182932. (doi: 10.1371/journal.pone.0182932) (PMID:28846711) (PMCID:PMC5573304)

Petrie, J. R. et al. (2017) Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(8), pp. 597-609. (doi: 10.1016/S2213-8587(17)30194-8) (PMID:28615149) (PMCID:PMC5641446)

Dobbin, S.J.H. , Petrie, J.R. , Lean, M.E.J. and McKay, G.A. (2017) Fludrocortisone therapy for persistent hyperkalaemia. Diabetic Medicine, 34(7), pp. 1005-1008. (doi: 10.1111/dme.13359) (PMID:28375568)

Akbar, T. et al. (2017) Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). International Journal of Epidemiology, 46(3), 796-796i. (doi: 10.1093/ije/dyw152) (PMID:28338705)

Bell, S. et al. (2017) Risk of acute kidney injury and survival in patients treated with metformin: an observational cohort study. BMC Nephrology, 18, 163. (doi: 10.1186/s12882-017-0579-5) (PMID:28526011) (PMCID:PMC5437411)

Natali, A., Baldi, S., Bonnet, F., Petrie, J. , Trifirò, S., Tricò, D. and Mari, A. (2017) Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects. Metabolism, 69, pp. 33-42. (doi: 10.1016/j.metabol.2017.01.001) (PMID:28285650)

Petrie, J.R. et al. (2017) Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. Diabetes, Obesity and Metabolism, 19(4), pp. 509-516. (doi: 10.1111/dom.12840) (PMID:27935183) (PMCID:PMC5357575)

Bonnet, F., Gastaledelli, A., Pihan-le Bars, F., Natali, A., Roussel, R., Petrie, J. , Tichet, J., Marre, M., Fromenty, B. and Balkau, B. (2017) Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. Journal of Hypertension, 35(3), pp. 493-500. (doi: 10.1097/HJH.0000000000001204) (PMID:27984413)

2016

Read, S. H. et al. (2016) Erratum to: Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 59(11), p. 2492. (doi: 10.1007/s00125-016-4089-y) (PMID:27465219) (PMCID:PMC5016553)

Read, S. H. et al. (2016) Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 59(10), pp. 2106-2113. (doi: 10.1007/s00125-016-4054-9) (PMID:27465219) (PMCID:PMC5016553)

Petrie, J. R. et al. (2016) LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. Journal of Hypertension, 34(6), pp. 1140-1150. (doi: 10.1097/HJH.0000000000000890) (PMID:26855018) (PMCID:PMC4856174)

Masmiquel, L. et al. (2016) LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology, 15(29), (doi: 10.1186/s12933-016-0341-5) (PMID:26864124) (PMCID:PMC4750199)

Nauck, M., Petrie, J. , Sesti, G., Mannucci, E., Courreges, J.-P., Lindegaard, M., Jensen, C. and Atkin, S. (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human glp-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care, 39(2), pp. 231-241. (doi: 10.2337/dc15-0165) (PMID:26358288)

2015

Connelly, P. , McKay, G. and Petrie, J. R. (2015) Metformin in type 1 diabetes. Practical Diabetes, 32(5), 186-187a. (doi: 10.1002/pdi.1954)

Heinemann, L., Fleming, G. A., Petrie, J. R. , Holl, R. W., Bergenstal, R. M. and Peters, A. L. (2015) Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs: a joint statement of the European association for the study of diabetes and the American diabetes association diabetes technology working group. Diabetologia, 58(5), pp. 862-870. (doi: 10.1007/s00125-015-3513-z) (PMID:25784563)

Seshasai, S.R.K., Bennett, R.L., Petrie, J.R. , Bengus, M., Ekman, S., Dixon, M., Herz, M., Buse, J.B. and Ray, K.K. (2015) Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 17(5), pp. 505-510. (doi: 10.1111/dom.12448) (PMID:25656522)

Malik, M. O. et al. (2015) Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia, 58(4), pp. 716-725. (doi: 10.1007/s00125-015-3492-0)

Livingstone, S. J. et al. (2015) Estimated life expectancy in a Scottish cohort With type 1 diabetes, 2008-2010. JAMA: Journal of the American Medical Association, 313(1), pp. 37-44. (doi: 10.1001/jama.2014.16425) (PMID:25562264) (PMCID:PMC4426486)

Vella, S. and Petrie, J. R. (2015) Macrovascular disease: pathogenesis and risk assessment. Medicine, 43(1), pp. 1-6. (doi: 10.1016/j.mpmed.2014.10.012)

Heinemann, L., Fleming, G. A., Petrie, J. , Holl, R. W., Bergenstal, R. M. and Peters, A. L. (2015) Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs. Diabetes Care, 38(4), pp. 716-722. (doi: 10.2337/dc15-0168) (PMID:25776138)

2014

Siwy, J. et al. (2014) Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 29(8), pp. 1563-1570. (doi: 10.1093/ndt/gfu039)

Petrie, J. R. (2014) Evidence-based estimation of insulin resistance. Diabetologia, 57(9), pp. 1743-1745. (doi: 10.1007/s00125-014-3322-9)

2013

Cleland, S.J., Fisher, B.M., Colhoun, H.M., Sattar, N. and Petrie, J.R. (2013) Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia, 56(7), pp. 1462-1470. (doi: 10.1007/s00125-013-2904-2)

Negandhi, P.H., Ghouri, N. , Colhoun, H.M., Fischbacher, C.M., Lindsay, R.S. , McKnight, J.A., Petrie, J. , Philip, S., Sattar, N. and Wild, S.H. (2013) Ethnic differences in Glycaemic control in people with type 2 diabetes mellitus living in Scotland. PLoS ONE, 8(12), e83292. (doi: 10.1371/journal.pone.0083292) (PMID:24358273) (PMCID:PMC3865180)

Petrie, J. , Malik, M.O., Balkau, B., Perry, C.G., Højlund, K., Pataky, Z., Nolan, J., Ferrannini, E. and Natali, A. (2013) Euglycemic clap insulin sensitivity and longitudinal systolic blood pressure: role of gender. Hypertension, 62(2), pp. 404-409. (doi: 10.1161/HYPERTENSIONAHA.111.00439)

Petrie, J.R. (2013) The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovascular Diabetology, 12(1), p. 130. (doi: 10.1186/1475-2840-12-130)

Ruiz-Alcaraz, A.J., Lipina, C., Petrie, J.R. , Murphy, M.J., Morris, A.D., Sutherland, C. and Cuthbertson, D.J. (2013) Obesity-induced insulin resistance in human skeletal muscle is characterised by defective activation of p42/p44 MAP kinase. PLoS ONE, 8(2), e56928. (doi: 10.1371/journal.pone.0056928) (PMID:23468892) (PMCID:PMC3585240)

2012

Jackson, C.A. et al. (2012) Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia, 55(11), pp. 2938-2945. (doi: 10.1007/s00125-012-2667-1)

Livingstone, S.J. et al. (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Medicine, 9(10), e1001321. (doi: 10.1371/journal.pmed.1001321)

Gadsby, R., Snow, R., Daly, A.C., Crowe, S., Matyka, K., Hall, B. and Petrie, J. (2012) Setting research priorities for Type 1 diabetes. Diabetic Medicine, (doi: 10.1111/j.1464-5491.2012.03755.x)

Wong, A.K.F., Symon, R., Alzadjali, M.A., Ang, D.S.C., Ogston, S., Choy, A., Petrie, J.R. , Struthers, A.D. and Lang, C.C. (2012) The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. European Journal of Heart Failure, (doi: 10.1093/eurjhf/hfs106)

Brown, K., Harbour, R. and Petrie, J. (2012) Evaluation of guidelines on diabetes medication. Annals of Internal Medicine, 156(10),

Handberg, A., Højlund, K., Gastaldelli, A., Flyvbjerg, A., Dekker, J.M., Petrie, J. , Piatti, P. and Beck-Nielsen, H. (2012) Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. Journal of Internal Medicine, 271(3), pp. 294-304. (doi: 10.1111/j.1365-2796.2011.02442.x)

2011

Strawbridge, R.J. et al. (2011) Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes, 60(10), pp. 2624-2634. (doi: 10.2337/db11-0415)

Petrie, J. R. , Pearson, E. R. and Sutherland, C. (2011) Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. Biochemical Pharmacology, 81(4), pp. 471-477. (doi: 10.1016/j.bcp.2010.11.010)

Govan, L. et al. (2011) Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 54(8), pp. 2000-2008. (doi: 10.1007/s00125-011-2176-7)

Kohlhaas, C.F., Morrow, V.A., Jhakra, N., Patil, V., Connell, J.M.C., Petrie, J.R. and Salt, I.P. (2011) Insulin rapidly stimulates l-arginine transport in human aortic endothelial cells via Akt. Biochemical and Biophysical Research Communications, 412(4), pp. 747-751. (doi: 10.1016/j.bbrc.2011.08.048)

Petrie, J.R. , Adler, A. and Vella, S. (2011) What to add in with metformin in type 2 diabetes? QJM: An International Journal of Medicine, 104(3), pp. 185-192. (doi: 10.1093/qjmed/hcq237)

2010

Sharma, G., Wilson, K. , van der Walle, C.F., Sattar, N. , Petrie, J.R. and Ravi Kumar, M.N.V. (2010) Microemulsions for oral delivery of insulin: Design, development and evaluation in streptozotocin induced diabetic rats. European Journal of Pharmaceutics and Biopharmaceutics, 76(2), pp. 159-169. (doi: 10.1016/j.ejpb.2010.07.002) (PMID:20655382)

Manco, M., Panunzi, S., Macfarlane, D.Y., Golay, A., Melander, O., Konrad, T., Petrie, J.R. and Mingrone, G. (2010) One-Hour plasma glucose identifies insulin resistance and β-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the relationship between insulin sensitivity and cardiovascular risk (RISC) study. Diabetes Care, 33(9), pp. 2090-2097. (doi: 10.2337/dc09-2261)

Vella, S., Buetow, L., Royle, P., Livingstone, S., Colhoun, H. M. and Petrie, J. R. (2010) The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 53(5), pp. 809-820. (doi: 10.1007/s00125-009-1636-9)

Anderwald, C., Stadler, M., Golay, A., Krebs, M., Petrie, J. and Luger, A. (2010) Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults. Heart, 96(15), pp. 1191-1200. (doi: 10.1136/hrt.2009.177436)

Evans, J. M.M., Doney, A. S.F., AlZadjali, M. A., Ogston, S. A., Petrie, J. R. , Morris, A. D., Struthers, A. D., Wong, A. K.F. and Lang, C. C. (2010) Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. American Journal of Cardiology, 106(7), pp. 1006-1010. (doi: 10.1016/j.amjcard.2010.05.031)

Ingelsson, E. et al. (2010) Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans. Diabetes, 59(5), pp. 1266-1275. (doi: 10.2337/DB09-1568)

Johnston, H., McCrimmon, R., Petrie, J. and Astell, A. (2010) An estimate of lifetime cognitive change and its relationship with diabetes health in older adults with type 1 diabetes: Preliminary results. Behavioural Neurology, 23(4), pp. 165-167. (doi: 10.3233/BEN-2010-0285)

MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D. , Bhagra, S., Jhund, P. S. , Petrie, M. C., McMurray, J. J. V. , Petrie, J.R. and McAlister, F. A. (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care, 33(6), pp. 1213-1218. (doi: 10.2337/dc09-2227)

Manco, M., Panunzi, S., Macfarlane, D. P., Golay, A., Melander, O., Konrad, T., Petrie, J. R. and Mingrone, G. (2010) One-Hour Plasma Glucose Identifies Insulin Resistance and β-Cell Dysfunction in Individuals With Normal Glucose Tolerance. Cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care, 33(9), pp. 2090-2097. (doi: 10.2337/dc09-2261)

Vella, S., Buetow, L., Royle, P., Livingstone, S. and Petrie, J. R. (2010) Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter]. Diabetologia, 54(1), pp. 203-204. (doi: 10.1007/s00125-010-1953-z)

2009

Natali, A., Muscelli, E., Casolaro, A., Nilsson, P., Melander, O., Lalic, N., Ferrannini, E. and Petrie, J. R. (2009) Metabolic characteristics of prehypertension: role of classification criteria and gender. Journal of Hypertension, 27(12), pp. 2394-2402. (doi: 10.1097/HJH.0b013e3283316c31)

Woods, Y.L., Petrie, J.R. and Sutherland, C. (2009) Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant states. Endocrine, Metabolic and Immune Disorders - Drug Targets, 9(2), pp. 187-198.

Muscelli, E., Kozàkovà, M., Flyvbjerg, A., Kyriakopoulou, K., Astiarraga, B. D., Glintborg, D., Konrad, T., Favuzzi, A. and Petrie, J. (2009) The Effect of Menopause on Carotid Artery Remodeling, Insulin Sensitivity, and Plasma Adiponectin in Healthy Women. American Journal of Hypertension, 22(4), pp. 364-370. (doi: 10.1038/ajh.2009.16)

Wong, A. K. F., Howie, J., Petrie, J. R. and Lang, C. C. (2009) AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clinical Science, 116(8), pp. 607-620. (doi: 10.1042/CS20080066)

Rajkhowa, M., Brett, S., Cuthbertson, D. J., Lipina, C., Ruiz-Alcaraz, A. J., Thomas, G. E., Logie, L., Petrie, J. and Sutherland, C. (2009) Insulin resistance in polycystic ovary syndrome is associated with defective regulation of ERK1/2 by insulin in skeletal muscle in vivo. Biochemical Journal, 418(3), pp. 665-671. (doi: 10.1042/BJ20082176)

ALZadjali, M. A., Godfrey, V., Khan, F., Choy, A., Doney, A. S., Wong, A. K., Petrie, J. R. , Struthers, A. D. and Lang, C. C. (2009) Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart Failure. Journal of the American College of Cardiology, 53(9), pp. 747-753. (doi: 10.1016/j.jacc.2008.08.081)

Petrie, J.R. (2009) Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 360(4), pp. 416-417.

2008

Patel, S., Flyvbjerg, A., Kozakova, M., Frystyk, J., Ibrahim, I. M., Petrie, J. R. , Avery, P. J., Ferrannini, E. and Walker, M. (2008) Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. European Heart Journal, 29(3), pp. 386-393. (doi: 10.1093/eurheartj/ehm526)

Bailey, C. J., Barnett, A. H. and Petrie, J. (2008) Value of glycaemic control in diabetes. Lancet, 371(9607), 116--. (doi: 10.1016/S0140-6736(08)60101-4)

MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Petrie, J.R. , Fisher, M., McKelvie, R., Aguilar, D., Krum, H. and McMurray, J.J.V. (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal, 29(10), pp. 1224-1240. (doi: 10.1093/eurheartj/ehn156)

2007

Gill, J.M. , Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Perry, C.G., Sattar, N. , Packard, C.J. , Caslake, M.J. and Petrie, J.R. (2007) Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: Heterogeneity of responses. Atherosclerosis, 194(1), pp. 134-143. (doi: 10.1016/j.atherosclerosis.2006.10.007)

Kernohan, A. F. B., Sattar, N., Hilditch, T., Cleland, S. J., Small, M., Lumsden, M. A., Connell, J. M. C. and Petrie, J. R. (2007) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clinical Endocrinology, 66(1), pp. 27-34. (doi: 10.1111/j.1365-2265.2006.02679.x)

Jadhav, S., Sattar, N., Petrie, J. , Cobbe, S. and Ferrell, W. (2007) Reproducibility and repeatability of peripheral microvascular assessment using lontophoresis in conjunction with laser doppler imaging. Journal of Cardiovascular Pharmacology, 50(3), pp. 343-349. (doi: 10.1097/FJC.0b013e3180dca094)

Sainsbury, C., Coleman, J., Brady, A., Connell, J., Hillier, C. and Petrie, J. (2007) Endothelium-dependent relaxation is resistant to inhibition of nitric oxide synthesis, but sensitive to blockade of calcium-activated potassium channels in essential hypertension. Journal of Human Hypertension, 21(10), pp. 808-814. (doi: 10.1038/sj.jhh.1002226)

2006

Gill, J. , Al-Mamari, A., Ferrell, W., Cleland, S., Sattar, N., Packard, C. , Petrie, J. and Caslake, M. (2006) Effects of a moderate exercise session on postprandial lipoproteins, apolipoproteins and lipoprotein remnants in middle-aged men. Atherosclerosis, 185(1), pp. 87-96. (doi: 10.1016/j.atherosclerosis.2005.06.009)

Jadhav, S., Ferrell, W., Greer, I., Petrie, J. , Cobbe, S. and Sattar, N. (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries - A randomized, double-blind, placebo-controlled study. Journal of the American College of Cardiology, 48(5), pp. 956-963. (doi: 10.1016/j.jacc.2006.04.088)

Jadhav, S., Ferrell, W., Petrie, J. , Scherbakova, O., Greer, I., Cobbe, S. and Sattar, N. (2006) Microvascular function, metabolic syndrome, and novel risk factor status in women with cardiac syndrome X. American Journal of Cardiology, 97(12), pp. 1727-1731. (doi: 10.1016/j.amjcard.2005.12.069)

2005

McCallum, R., Sainsbury, C., Spiers, A., Dominiczak, A., Petrie, J. , Sattar, N. and Connell, J. (2005) Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clinical Endocrinology, 62(4), pp. 473-479. (doi: 10.1111/j.1365-2265.2005.02245.x)

McDougall, C., Brady, A.J.B. and Petrie, J.R. (2005) ASCOT: a tale of two treatment regimens. British Medical Journal, 331(7521), p. 859. (doi: 10.1136/bmj.331.7521.859)

2004

Gill, J.M.R., Al-Mamari, A., Ferrell, W.R., Cleland, S.J., Packard, C.J. , Sattar, N. , Petrie, J.R. and Caslake, M.J. (2004) Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. Journal of the American College of Cardiology, 44(12), pp. 2375-2382. (doi: 10.1016/j.jacc.2004.09.035)

Jadhav, S., Petrie, J. , Ferrell, W., Cobbe, S. and Sattar, N. (2004) Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation? Heart, 90(12), pp. 1379-1383. (doi: 10.1136/hrt.2004.035170)

McEleavy, O., McCallum, R., Petrie, J. , Small, M., Connell, J., Sattar, N. and Cleland, S. (2004) Higher carotid-radial pulse wave velocity in healthy offspring of patients with Type 2 diabetes. Diabetic Medicine, 21(3), pp. 262-266. (doi: 10.1111/j.1464-5491.2004.01127.x)

Perry, C., Cleland, S., Connell, J., Petrie, J. and Sattar, N. (2004) Low grade inflammation is notably suppressed by conventional anti-inflammatory treatment: a randomised crossover trial. Heart, 90(7), pp. 804-805. (doi: 10.1136/hrt.2003.022129)

Sainsbury, C., Sattar, N., Connell, J., Hillier, C. and Petrie, J. (2004) Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels. Clinical Science, 107(6), pp. 625-629.

2003

McDougall, C., Stanley, A., Sattar, N. , Perry, C. and Petrie, J. (2003) Severe hypertriglyceridaemia with splenomegaly in type 2 diabetes. British Journal of Diabetes and Vascular Disease, 3(3), pp. 227-228. (doi: 10.1177/14746514030030031301)

McDougall, C., Perry, C., Sattar, N. and Petrie, J. (2003) Statins in the era of evidence-based medicine - who will not 'prosper'? Scottish Medical Journal, 48(3), pp. 64-68.

McKenzie, J. et al. (2003) Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clinical Endocrinology, 59(6), pp. 682-689. (doi: 10.1046/j.1365-2265.2003.01906.x)

Morrow, V., Foufelle, F., Connell, J., Petrie, J. , Gould, G. and Salt, I. (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. Journal of Biological Chemistry, 278(34), pp. 31629-31639. (doi: 10.1074/jbc.M212831200)

Perry, C.G., Spiers, A., Cleland, S.J., Lowe, G.D.O., Petrie, J.R. and Connell, J.M.C. (2003) Glucocorticoids and insulin sensitivity: dissociation of insulin's metabolic and vascular actions. Journal of Clinical Endocrinology and Metabolism, 88(12), pp. 6008-6014. (doi: 10.1210/jc.2002-021605)

Perry, C., Palmer, T., Cleland, S., Morton, I., Salt, I. , Petrie, J. , Gould, G. and Connell, J. (2003) Decreased insulin sensitivity during dietary sodium restriction is not mediated by effects of angiotensin II on insulin action. Clinical Science, 105(2), pp. 187-194. (doi: 10.1042/CS20020320)

Salt, I., Morrow, V., Brandie, F., Connell, J. and Petrie, J. (2003) High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser(1177) phosphorylation in human aortic endothelial cells. Journal of Biological Chemistry, 278(21), pp. 18791-18797. (doi: 10.1074/jbc.M210618200)

2002

Duncan, A. C., Petrie, J. R. , Brosnan, M. J., Devlin, A. M., Bass, R. A., Charnock-Jones, D. S., Connell, J. M., Dominiczak, A. F. and Lumsden, M. A. (2002) Is estradiol cardioprotection a nitric oxide-mediated effect? Human Reproduction, 17(7), pp. 1918-1924. (doi: 10.1093/humrep/17.7.1918)

Kelly, C.J.G., Lyall, H., Petrie, J.R. , Gould, G.W. , Connell, J.M.C., Rumley, A., Lowe, G.D.O. and Sattar, N. (2002) A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 87(7), pp. 3287-3290. (doi: 10.1210/jc.87.7.3287)

Kelly, C., Speirs, A., Gould, G., Petrie, J. , Lyall, H. and Connell, J. (2002) Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 87(2), pp. 742-746. (doi: 10.1210/jc.87.2.742)

McCallum, R., Petrie, J. , Dominiczak, A. and Connell, J. (2002) Growth hormone deficiency and vascular risk. Clinical Endocrinology, 57(1), pp. 11-24. (doi: 10.1046/j.1365-2265.2002.01559.x)

Perera, M., Petrie, J. , Hillier, C., Small, M., Sattar, N., Connell, J. and Lumsden, M. (2002) Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Human Reproduction, 17(2), pp. 497-502. (doi: 10.1093/humrep/17.2.497)

2001

Kelly, C., Lyall, H., Petrie, J. , Gould, G., Connell, J. and Sattar, N. (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 86(6), pp. 2453-2455. (doi: 10.1210/jc.86.6.2453)

Perera, M., Sattar, N. , Petrie, J.R. , Hillier, C., Small, M., Connell, J.M.C., Lowe, G.D.O. and Lumsden, M.A. (2001) The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 86(3), pp. 1140-1143. (doi: 10.1210/jc.86.3.1140)

Petrie, J. , Collison, M., Connell, J., Gould, G. and Dominiczak, A. (2001) CD36 deficiency and insulin resistance. Lancet, 358(9277), pp. 242-243. (doi: 10.1016/S0140-6736(01)05428-9)

This list was generated on Fri Apr 26 11:42:15 2024 BST.

Jump to: Articles | Book Sections